19.02.2004 – 07:36
Jacobson Resonance Enterprise, Inc. Receives Allowance From FDA to "Enhance Feelings of Relaxation" With the Jacobson Resonator
BOYNTON BEACH, FL (ots)
Jacobson Resonance Enterprises, Inc. (OTC BB: JRSE) announced today that the United States Food and Drug Administration has granted an allowance to implement our state-of-the-art Jacobson Resonance Technology in the multi-billion dollar leisure/spa arena for relaxation purposes. Specifically, JRSE submitted an application in accordance with Section 513(g) of the Federal Food, Drug, and Cosmetic Act and was granted an allowance by the Center for Devices and Radiological Health (CDR1-1) for the indication designated as to "enhance feelings of relaxation."
Dr. Jerry I. Jacobson, Chairman of the Board, Chief Executive Officer and Chief Science and Technology Officer of JRSE shares; "After twenty-four years of theorizing I am witnessing a dream come true, the reality of a vision. The vision was one of hope and love for all humans, for what the future could bring with the Unified-Field Equation mc squared = Bvlq. Magnetism may be utilized to enhance feelings of relaxation. We use the lowest level of magnetic fields non-invasively. The FDA has recognized, in my opinion that static magnetic fields are in use all over the world for the specific indication of relaxation. We plan now to enter into the spa and leisure arenas worldwide including resorts and cruise ships. Chiropractors and a variety of healthcare providers will also benefit from this technology. The markets are numerous and we believe this technology will become widespread for the betterment of all mankind."
Harvey Grossman, President and Chief Strategic Officer of JRSE also shares; "I am both excited and humbled by the potential good for our shareholders and all humanity this FDA allowance brings. After many long years of ups and downs like the Cyclone Rollercoaster, JRSE has endured for one reason and one reason only. The discovery that Dr. Jacobson made in 1979 has been validated through rigorous science and an adventurer's spirit. Let us all rejoice in the potential benefits that this allowance brings and may we all pray for the guidance necessary to follow the right path for the benefit of all involved."
Anthony P. Fusco, JR., Vice President and Chief Operating Officer of JRSE additionally shares; "In the short time that I have been a member of the JRSE team I have witnessed many astonishing and enlightening events that can only attest to the origin of the Discovery and its purpose to help mankind. Today the light is shining on an integral part of the JRSE mosaic. This confirmation of our technology in the USA will allow us to implement an important aspect of our business model."
Additional news releases in the near future will provide more information about the application of this FDA allowance into revenue producing projects.
Dr. Jacobson and Mr. Grossman are hosting a JRSE/Magnetic Resonance Therapy (Bahamas), Limited "Educational & Business Development Retreat" in New Providence, Nassau, Bahamas from Thursday, February 26 through Sunday Morning, February 29, 2004. The purpose of this pivotal gathering is to discern the most correct path to follow in order to fulfil the often stated mission of this corporation, the eradication of human suffering while providing a fair return to our investors. Additionally, both tactical and strategic plans will be developed in order to expedite the creation of long-awaited revenues. For further information concerning attendance at this historical retreat, please call Anthony P. Fusco JR., international headquarters, Boynton Beach, Florida, USA, at 561.752.4141.
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, spa and leisure arena, food and beverage, pharmaceuticals, energy and the environment.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances.
ots Original Text Service: Jacobson Resonance Enterprise, Inc. Internet: http://www.presseportal.ch
For further information, contact: Anthony Fusco Jr. (561) 752.4141